{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T18:07:47Z","timestamp":1791655667633,"version":"4.3.4"},"reference-count":100,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T00:00:00Z","timestamp":1783296000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T00:00:00Z","timestamp":1783296000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"AstraZeneca and Merck Sharp & Dohme LLC"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Transl Oncol"],"DOI":"10.1007\/s12094-026-04467-6","type":"journal-article","created":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T17:19:35Z","timestamp":1783358375000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Multidisciplinary management of advanced ovarian cancer in Spain: expert recommendations for achieving maximum survival and improving patient care"],"prefix":"10.1007","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0074-6614","authenticated-orcid":false,"given":"Maria-Pilar","family":"Barretina-Ginesta","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7166-9762","authenticated-orcid":false,"given":"Ainhoa","family":"Madariaga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manel","family":"Barahona Orpinell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5556-0449","authenticated-orcid":false,"given":"Alejandro","family":"Gallego","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-5556-2337","authenticated-orcid":false,"given":"Eva Mar\u00eda","family":"Guerra Al\u00eda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7201-6605","authenticated-orcid":false,"given":"Xavier","family":"Matias-Guiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1742-5374","authenticated-orcid":false,"given":"Ana Beatriz","family":"Sanchez Heras","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9755-352X","authenticated-orcid":false,"given":"Soraya","family":"Casla-Barrio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-7790-2379","authenticated-orcid":false,"given":"F\u00e1tima","family":"Casta\u00f1o","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1545-1982","authenticated-orcid":false,"given":"Melinda","family":"Gonzalez Concepci\u00f3n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar","family":"Navarro L\u00f3pez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charo","family":"Hierro Racionero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcelo","family":"Ruz Torres","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6898-0557","authenticated-orcid":false,"given":"Lydia","family":"Gaba Garc\u00eda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,6]]},"reference":[{"key":"4467_CR1","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3322\/caac.21834","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74:229\u201363. https:\/\/doi.org\/10.3322\/caac.21834.","journal-title":"CA Cancer J Clin"},{"key":"4467_CR2","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1186\/s13048-021-00816-x","volume":"14","author":"A Redondo","year":"2021","unstructured":"Redondo A, Oaknin A, Rubio MJ, Barretina-Ginesta M-P, de Juan A, Manso L, et al. Management of advanced ovarian cancer in Spain: an expert Delphi consensus. J Ovarian Res. 2021;14:72. https:\/\/doi.org\/10.1186\/s13048-021-00816-x.","journal-title":"J Ovarian Res"},{"key":"4467_CR3","unstructured":"Sociedad Espa\u00f1ola de Oncolog\u00eda M\u00e9dica. Las cifras del c\u00e1ncer en Espa\u00f1a 2026. Dep\u00f3sito Leg M-3132-2026. 2025;ISBN: 978-84-09-82151-8."},{"key":"4467_CR4","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1111\/hex.13681","volume":"26","author":"C Vela-Vallesp\u00edn","year":"2023","unstructured":"Vela-Vallesp\u00edn C, Medina-Perucha L, Jacques-Avi\u00f1\u00f3 C, Codern-Bov\u00e9 N, Harris M, Borras JM, et al. Women\u2019s experiences along the ovarian cancer diagnostic pathway in Catalonia: a qualitative study. Health Expect. 2023;26:476\u201387. https:\/\/doi.org\/10.1111\/hex.13681.","journal-title":"Health Expect"},{"key":"4467_CR5","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1016\/j.annonc.2023.07.011","volume":"34","author":"A Gonz\u00e1lez-Mart\u00edn","year":"2023","unstructured":"Gonz\u00e1lez-Mart\u00edn A, Harter P, Leary A, Lorusso D, Miller RE, Pothuri B, et al. Newly diagnosed and relapsed epithelial ovarian cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol. 2023;34:833\u201348. https:\/\/doi.org\/10.1016\/j.annonc.2023.07.011.","journal-title":"Ann Oncol"},{"key":"4467_CR6","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1016\/j.annonc.2023.11.015","volume":"35","author":"JA Ledermann","year":"2024","unstructured":"Ledermann JA, Matias-Guiu X, Amant F, Concin N, Davidson B, Fotopoulou C, et al. ESGO\u2013ESMO\u2013ESP consensus conference recommendations on ovarian cancer: pathology and molecular biology and early, advanced and recurrent disease. Ann Oncol. 2024;35:248\u201366. https:\/\/doi.org\/10.1016\/j.annonc.2023.11.015.","journal-title":"Ann Oncol"},{"key":"4467_CR7","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1007\/s12672-025-02725-7","volume":"16","author":"F Cheng","year":"2025","unstructured":"Cheng F, Shao F, Tian Y, Chen S. Genomic and clinical insights into ovarian cancer: subtype-specific alterations and predictors of metastasis and relapse. Discov Oncol. 2025;16:907. https:\/\/doi.org\/10.1007\/s12672-025-02725-7.","journal-title":"Discov Oncol"},{"key":"4467_CR8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3892\/ijo.2021.5233","volume":"59","author":"L Falzone","year":"2021","unstructured":"Falzone L, Scandurra G, Lombardo V, Gattuso G, Lavoro A, Distefano AB, et al. A multidisciplinary approach remains the best strategy to improve and strengthen the management of ovarian cancer. Int J Oncol. 2021;59:1\u201314. https:\/\/doi.org\/10.3892\/ijo.2021.5233.","journal-title":"Int J Oncol"},{"key":"4467_CR9","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2022.102396","author":"H Woopen","year":"2022","unstructured":"Woopen H, Sehouli J, Davis A, Lee YC, Cohen PA, Ferrero A, et al. GCIG-Consensus guideline for long-term survivorship in gynecologic cancer: a position paper from the gynecologic cancer Intergroup (GCIG) symptom benefit committee. Cancer Treat Rev. 2022. https:\/\/doi.org\/10.1016\/j.ctrv.2022.102396.","journal-title":"Cancer Treat Rev"},{"key":"4467_CR10","doi-asserted-by":"publisher","DOI":"10.1007\/s12094-025-04127-1","author":"A Madariaga","year":"2025","unstructured":"Madariaga A, Cots M, Hierro C, Robles C, Garrido S, Barretina-Ginesta M-P, et al. Needs and opportunities for improvement in the management and monitoring of gynaecological cancer in Spain. Clin Transl Oncol. 2025. https:\/\/doi.org\/10.1007\/s12094-025-04127-1.","journal-title":"Clin Transl Oncol"},{"key":"4467_CR11","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/j.annonc.2022.10.004","volume":"34","author":"C Sessa","year":"2023","unstructured":"Sessa C, Balma\u00f1a J, Bober SL, Cardoso MJ, Colombo N, Curigliano G, et al. Risk reduction and screening of cancer in hereditary breast-ovarian cancer syndromes: ESMO clinical practice guideline. Ann Oncol. 2023;34:33\u201347. https:\/\/doi.org\/10.1016\/j.annonc.2022.10.004.","journal-title":"Ann Oncol"},{"key":"4467_CR12","doi-asserted-by":"publisher","first-page":"1432901","DOI":"10.3389\/frhs.2024.1432901","volume":"4","author":"W Jerjes","year":"2024","unstructured":"Jerjes W, Harding D. Enhancing primary care through integrated care pathways: a convergence of theory and practice. Front Health Serv. 2024;4:1432901. https:\/\/doi.org\/10.3389\/frhs.2024.1432901.","journal-title":"Front Health Serv"},{"key":"4467_CR13","doi-asserted-by":"publisher","first-page":"2072","DOI":"10.3390\/diagnostics13122072","volume":"13","author":"K Dinneen","year":"2023","unstructured":"Dinneen K, Arora R. Molecular testing in ovarian tumours: challenges from the pathologist\u2019s perspective. Diagn. 2023;13:2072. https:\/\/doi.org\/10.3390\/diagnostics13122072.","journal-title":"Diagn"},{"key":"4467_CR14","doi-asserted-by":"publisher","first-page":"S119","DOI":"10.1097\/PGP.0000000000000908","volume":"41","author":"CB Gilks","year":"2022","unstructured":"Gilks CB, Selinger CI, Davidson B, K\u00f6bel M, Ledermann JA, Lim D, et al. Data set for the reporting of ovarian, fallopian tube and primary peritoneal carcinoma: recommendations from the International Collaboration on Cancer Reporting (ICCR). Int J Gynecol Pathol. 2022;41:S119. https:\/\/doi.org\/10.1097\/PGP.0000000000000908.","journal-title":"Int J Gynecol Pathol"},{"key":"4467_CR15","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1007\/s12094-017-1719-x","volume":"20","author":"A Oaknin","year":"2018","unstructured":"Oaknin A, Guarch R, Barretina P, Hardisson D, Gonz\u00e1lez-Mart\u00edn A, Mat\u00edas-Guiu X, et al. Recommendations for biomarker testing in epithelial ovarian cancer: a national consensus statement by the Spanish society of pathology and the Spanish society of medical oncology. Clin Transl Oncol. 2018;20:274\u201385. https:\/\/doi.org\/10.1007\/s12094-017-1719-x.","journal-title":"Clin Transl Oncol"},{"key":"4467_CR16","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1200\/EDBK_350292","volume":"42","author":"MK Frey","year":"2022","unstructured":"Frey MK, Finch A, Kulkarni A, Akbari MR, Chapman-Davis E. Genetic testing for all: overcoming disparities in ovarian cancer genetic testing. Am Soc Clin Oncol Educ Book. 2022;42:471\u201382. https:\/\/doi.org\/10.1200\/EDBK_350292.","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"4467_CR17","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1038\/s41431-023-01507-5","volume":"32","author":"T McDevitt","year":"2024","unstructured":"McDevitt T, Durkie M, Arnold N, Burghel GJ, Butler S, Claes KBM, et al. EMQN best practice guidelines for genetic testing in hereditary breast and ovarian cancer. Eur J Hum Genet. 2024;32:479\u201388. https:\/\/doi.org\/10.1038\/s41431-023-01507-5.","journal-title":"Eur J Hum Genet"},{"key":"4467_CR18","doi-asserted-by":"publisher","first-page":"1234","DOI":"10.1002\/cncr.24149","volume":"115","author":"A du Bois","year":"2009","unstructured":"du Bois A, Reuss A, Pujade-Lauraine E, Harter P, Ray-Coquard I, Pfisterer J. Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer: a combined exploratory analysis of 3 prospectively randomized phase 3 multicenter trials. Cancer. 2009;115:1234\u201344. https:\/\/doi.org\/10.1002\/cncr.24149.","journal-title":"Cancer"},{"key":"4467_CR19","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1016\/j.ygyno.2010.05.025","volume":"118","author":"RE Bristow","year":"2010","unstructured":"Bristow RE, Palis BE, Chi DS, Cliby WA. The National cancer database report on advanced-stage epithelial ovarian cancer: impact of hospital surgical case volume on overall survival and surgical treatment paradigm. Gynecol Oncol. 2010;118:262\u20137. https:\/\/doi.org\/10.1016\/j.ygyno.2010.05.025.","journal-title":"Gynecol Oncol"},{"key":"4467_CR20","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1016\/j.ygyno.2016.05.025","volume":"142","author":"P Dahm-K\u00e4hler","year":"2016","unstructured":"Dahm-K\u00e4hler P, Palmqvist C, Staf C, Holmberg E, Johannesson L. Centralized primary care of advanced ovarian cancer improves complete cytoreduction and survival - A population-based cohort study. Gynecol Oncol. 2016;142:211\u20136. https:\/\/doi.org\/10.1016\/j.ygyno.2016.05.025.","journal-title":"Gynecol Oncol"},{"key":"4467_CR21","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1136\/ijgc-2020-001248","volume":"30","author":"C Fotopoulou","year":"2020","unstructured":"Fotopoulou C, Concin N, Planchamp F, Morice P, Vergote I, du Bois A, et al. Quality indicators for advanced ovarian cancer surgery from the European Society of Gynaecological Oncology (ESGO): 2020 update. Int J Gynecol Cancer. 2020;30:436\u201340. https:\/\/doi.org\/10.1136\/ijgc-2020-001248.","journal-title":"Int J Gynecol Cancer"},{"key":"4467_CR22","first-page":"90","volume":"65","author":"S Domingo del Pozo","year":"2022","unstructured":"Domingo del Pozo S, Lago Leal V, Coronado Mart\u00edn PJ, Tejerizo Garc\u00eda \u00c1, Mancebo Moreno G, S\u00e1nchez Iglesias JL, et al. C\u00e1ncer de ovario 2022. Prog Obstet Ginecol. 2022;65:90\u2013131.","journal-title":"Prog Obstet Ginecol"},{"key":"4467_CR23","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1007\/s00404-019-05321-7","volume":"301","author":"S Schneider","year":"2020","unstructured":"Schneider S, Armbrust R, Spies C, du Bois A, Sehouli J. Prehabilitation programs and ERAS protocols in gynecological oncology: a comprehensive review. Arch Gynecol Obstet. 2020;301:315\u201326. https:\/\/doi.org\/10.1007\/s00404-019-05321-7.","journal-title":"Arch Gynecol Obstet"},{"key":"4467_CR24","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.ygyno.2020.12.035","volume":"161","author":"SP Bisch","year":"2021","unstructured":"Bisch SP, Jago CA, Kalogera E, Ganshorn H, Meyer LA, Ramirez PT, et al. Outcomes of enhanced recovery after surgery (ERAS) in gynecologic oncology \u2013 A systematic review and meta-analysis. Gynecol Oncol. 2021;161:46\u201355. https:\/\/doi.org\/10.1016\/j.ygyno.2020.12.035.","journal-title":"Gynecol Oncol"},{"key":"4467_CR25","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.ygyno.2023.04.009","volume":"173","author":"G Nelson","year":"2023","unstructured":"Nelson G, Fotopoulou C, Taylor J, Glaser G, Bakkum-Gamez J, Meyer LA, et al. Enhanced recovery after surgery (ERAS\u00ae) society guidelines for gynecologic oncology: addressing implementation challenges - 2023 update. Gynecol Oncol. 2023;173:58\u201367. https:\/\/doi.org\/10.1016\/j.ygyno.2023.04.009.","journal-title":"Gynecol Oncol"},{"key":"4467_CR26","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1136\/ijgc-2022-004149","volume":"33","author":"G Caruso","year":"2023","unstructured":"Caruso G, Tomao F, Parma G, Lapresa M, Multinu F, Palaia I, et al. Poly (ADP-ribose) polymerase inhibitors (PARPi) in ovarian cancer: lessons learned and future directions. Int J Gynecol Cancer. 2023;33:431\u201343. https:\/\/doi.org\/10.1136\/ijgc-2022-004149.","journal-title":"Int J Gynecol Cancer"},{"key":"4467_CR27","doi-asserted-by":"publisher","first-page":"e390876","DOI":"10.1200\/EDBK_390876","volume":"43","author":"M Friedlander","year":"2023","unstructured":"Friedlander M, Lee YC, Tew WP. Managing adverse effects associated with poly (ADP-ribose) polymerase inhibitors in ovarian cancer: a synthesis of clinical trial and real-world data. Am Soc Clin Oncol Educ Book. 2023;43:e390876. https:\/\/doi.org\/10.1200\/EDBK_390876.","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"4467_CR28","unstructured":"Rieger PT, Yarbro CH. Role of the oncology nurse. In: Holland-Frei Cancer Medicine. 6th edition. BC Decker;2003"},{"key":"4467_CR29","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1634\/theoncologist.7-suppl_5-11","volume":"7","author":"CJ Dunton","year":"2002","unstructured":"Dunton CJ. Management of Treatment-Related Toxicity in Advanced Ovarian Cancer. Oncol. 2002;7:11\u20139. https:\/\/doi.org\/10.1634\/theoncologist.7-suppl_5-11.","journal-title":"Oncol"},{"key":"4467_CR30","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1517\/14740338.6.5.609","volume":"6","author":"NI Marupudi","year":"2007","unstructured":"Marupudi NI, Han JE, Li KW, Renard VM, Tyler BM, Brem H. Paclitaxel: a review of adverse toxicities and novel delivery strategies. Expert Opin Drug Saf. 2007;6:609\u201321. https:\/\/doi.org\/10.1517\/14740338.6.5.609.","journal-title":"Expert Opin Drug Saf"},{"key":"4467_CR31","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1016\/j.ygyno.2010.02.021","volume":"117","author":"LM Randall","year":"2010","unstructured":"Randall LM, Monk BJ. Bevacizumab toxicities and their management in ovarian cancer. Gynecol Oncol. 2010;117:497\u2013504. https:\/\/doi.org\/10.1016\/j.ygyno.2010.02.021.","journal-title":"Gynecol Oncol"},{"key":"4467_CR32","doi-asserted-by":"publisher","first-page":"e122","DOI":"10.1016\/S2352-3026(20)30360-4","volume":"8","author":"P-M Morice","year":"2021","unstructured":"Morice P-M, Leary A, Dolladille C, Chr\u00e9tien B, Poulain L, Gonz\u00e1lez-Mart\u00edn A, et al. Myelodysplastic syndrome and acute myeloid leukaemia in patients treated with PARP inhibitors: a safety meta-analysis of randomised controlled trials and a retrospective study of the WHO pharmacovigilance database. Lancet Haematol. 2021;8:e122\u201334. https:\/\/doi.org\/10.1016\/S2352-3026(20)30360-4.","journal-title":"Lancet Haematol"},{"key":"4467_CR33","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/j.ygyno.2024.07.006","volume":"189","author":"MR Kamrava","year":"2024","unstructured":"Kamrava MR, Gonzalez-Martin A, Pothuri B, Vergote I, Graybill W, Mirza MR, et al. Patterns of initial ovarian cancer recurrence on niraparib maintenance monotherapy in patients with no baseline evidence of disease after first-line chemotherapy: an ad hoc subgroup analysis of PRIMA\/ENGOT-OV26\/GOG-3012. Gynecol Oncol. 2024;189:68\u201374. https:\/\/doi.org\/10.1016\/j.ygyno.2024.07.006.","journal-title":"Gynecol Oncol"},{"key":"4467_CR34","doi-asserted-by":"publisher","first-page":"1164","DOI":"10.1136\/ijgc-2022-003543","volume":"32","author":"E Palluzzi","year":"2022","unstructured":"Palluzzi E, Marchetti C, Cappuccio S, Avesani G, Macchia G, Gambacorta MA, et al. Management of oligometastatic ovarian cancer recurrence during PARP inhibitor maintenance. Int J Gynecol Cancer. 2022;32:1164\u201370. https:\/\/doi.org\/10.1136\/ijgc-2022-003543.","journal-title":"Int J Gynecol Cancer"},{"key":"4467_CR35","doi-asserted-by":"publisher","first-page":"E1","DOI":"10.1188\/03.ONF.E1-E11","volume":"30","author":"BR Ferrell","year":"2003","unstructured":"Ferrell BR, Virani R, Smith S, Juarez G. The role of oncology nursing to ensure quality care for cancer survivors: a report commissioned by the national cancer policy board and institute of medicine. Oncol Nurs Forum. 2003;30:E1-11. https:\/\/doi.org\/10.1188\/03.ONF.E1-E11.","journal-title":"Oncol Nurs Forum"},{"key":"4467_CR36","doi-asserted-by":"publisher","first-page":"1702","DOI":"10.1002\/pon.6220","volume":"32","author":"RS Vicente","year":"2023","unstructured":"Vicente RS, Freitas AR, Ferreira RMA, Prada SP, Martins TS, Martins TC, et al. Communication preferences and perceptions of cancer patient during their first medical oncology appointment. Psychooncol. 2023;32:1702\u20139. https:\/\/doi.org\/10.1002\/pon.6220.","journal-title":"Psychooncol"},{"key":"4467_CR37","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1016\/j.ygyno.2017.08.030","volume":"147","author":"J Lilyquist","year":"2017","unstructured":"Lilyquist J, LaDuca H, Polley E, Davis BT, Shimelis H, Hu C, et al. Frequency of mutations in a large series of clinically ascertained ovarian cancer cases tested on multi-gene panels compared to reference controls. Gynecol Oncol. 2017;147:375\u201380. https:\/\/doi.org\/10.1016\/j.ygyno.2017.08.030.","journal-title":"Gynecol Oncol"},{"key":"4467_CR38","doi-asserted-by":"publisher","DOI":"10.1002\/jgc4.1940","volume":"34","author":"L Carlsson","year":"2024","unstructured":"Carlsson L, Bedard PL, Kim RH, Metcalfe K. Psychological distress following multi-gene panel testing for hereditary breast and ovarian cancer risk. J Genet Couns. 2024;34:e1940. https:\/\/doi.org\/10.1002\/jgc4.1940.","journal-title":"J Genet Couns"},{"key":"4467_CR39","doi-asserted-by":"publisher","DOI":"10.1002\/jgc4.70032","volume":"34","author":"E Cilli","year":"2025","unstructured":"Cilli E, Brancati F, Di Giacomo D. Perceived cancer risk and genetic counseling: a biopsychological perspective. J Genet Couns. 2025;34:e70032. https:\/\/doi.org\/10.1002\/jgc4.70032.","journal-title":"J Genet Couns"},{"key":"4467_CR40","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1002\/jgc4.1374","volume":"30","author":"JL Berliner","year":"2021","unstructured":"Berliner JL, Cummings SA, Boldt Burnett B, Ricker CN. Risk assessment and genetic counseling for hereditary breast and ovarian cancer syndromes\u2014Practice resource of the national society of genetic counselors. J Genet Couns. 2021;30:342\u201360. https:\/\/doi.org\/10.1002\/jgc4.1374.","journal-title":"J Genet Couns"},{"key":"4467_CR41","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1002\/pon.5551","volume":"30","author":"JH Tan","year":"2021","unstructured":"Tan JH, Sharpe L, Russell H. The impact of ovarian cancer on individuals and their caregivers: a qualitative analysis. Psychooncol. 2021;30:212\u201320. https:\/\/doi.org\/10.1002\/pon.5551.","journal-title":"Psychooncol"},{"key":"4467_CR42","doi-asserted-by":"publisher","DOI":"10.1111\/ecc.13645","volume":"31","author":"S-A Boding","year":"2022","unstructured":"Boding S-A, Russell H, Knoetze R, Wilson V, Stafford L. \u2018Sometimes I can\u2019t look in the mirror\u2019: recognising the importance of the sociocultural context in patient experiences of sexuality, relationships and body image after ovarian cancer. Eur J Cancer Care (Engl). 2022;31:e13645. https:\/\/doi.org\/10.1111\/ecc.13645.","journal-title":"Eur J Cancer Care (Engl)"},{"key":"4467_CR43","doi-asserted-by":"publisher","first-page":"1801","DOI":"10.1002\/cam4.4976","volume":"12","author":"S Hu","year":"2023","unstructured":"Hu S, Baraghoshi D, Chang C-P, Rowe K, Snyder J, Deshmukh V, et al. Mental health disorders among ovarian cancer survivors in a population-based cohort. Cancer Med. 2023;12:1801\u201312. https:\/\/doi.org\/10.1002\/cam4.4976.","journal-title":"Cancer Med"},{"key":"4467_CR44","doi-asserted-by":"publisher","first-page":"2408","DOI":"10.1002\/pon.3322","volume":"22","author":"KB Roland","year":"2013","unstructured":"Roland KB, Rodriguez JL, Patterson JR, Trivers KF. A literature review of the social and psychological needs of ovarian cancer survivors. Psychooncol. 2013;22:2408\u201318. https:\/\/doi.org\/10.1002\/pon.3322.","journal-title":"Psychooncol"},{"key":"4467_CR45","doi-asserted-by":"publisher","first-page":"279","DOI":"10.3390\/medicina61020279","volume":"61","author":"T Anghel","year":"2025","unstructured":"Anghel T, Melania BL, Costea I, Albai O, Marinca A, Levai CM, et al. Review of psychological interventions in oncology: current trends and future directions. Medicina (Mex). 2025;61:279. https:\/\/doi.org\/10.3390\/medicina61020279.","journal-title":"Medicina (Mex)"},{"key":"4467_CR46","doi-asserted-by":"publisher","first-page":"892","DOI":"10.3390\/jpm14090892","volume":"14","author":"G Perna","year":"2024","unstructured":"Perna G, Pinto E, Spiti A, Torti T, Cucchi M, Caldirola D. Foundations for a personalized psycho-oncology: the state of the art. J Pers Med. 2024;14:892. https:\/\/doi.org\/10.3390\/jpm14090892.","journal-title":"J Pers Med"},{"key":"4467_CR47","doi-asserted-by":"publisher","DOI":"10.1002\/pon.6280","volume":"33","author":"SA Yeoh","year":"2024","unstructured":"Yeoh SA, Webb S, Phillips A, Li LSK, Kumar S. Psychosocial interventions for ovarian cancer survivors: a systematic review. Psychooncology. 2024;33:e6280. https:\/\/doi.org\/10.1002\/pon.6280.","journal-title":"Psychooncology"},{"key":"4467_CR48","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1111\/j.1745-7599.2012.00732.x","volume":"24","author":"J Guenther","year":"2012","unstructured":"Guenther J, Stiles A, Champion JD. The lived experience of ovarian cancer: a phenomenological approach. J Am Acad Nurse Pract. 2012;24:595\u2013603. https:\/\/doi.org\/10.1111\/j.1745-7599.2012.00732.x.","journal-title":"J Am Acad Nurse Pract"},{"key":"4467_CR49","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1002\/pon.4952","volume":"28","author":"L Jelicic","year":"2019","unstructured":"Jelicic L, Brooker J, Shand L, Knight T, Ricciardelli L, Denham G, et al. Experiences and health care preferences of women with ovarian cancer during the diagnosis phase. Psychooncology. 2019;28:379\u201385. https:\/\/doi.org\/10.1002\/pon.4952.","journal-title":"Psychooncology"},{"key":"4467_CR50","doi-asserted-by":"publisher","first-page":"33","DOI":"10.2147\/PROM.S272688","volume":"12","author":"S Boban","year":"2021","unstructured":"Boban S, Downs J, Codde J, Cohen PA, Bulsara C. Women diagnosed with ovarian cancer: patient and carer experiences and perspectives. Patient Relat Outcome Meas. 2021;12:33\u201343. https:\/\/doi.org\/10.2147\/PROM.S272688.","journal-title":"Patient Relat Outcome Meas"},{"key":"4467_CR51","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejon.2023.102487","volume":"68","author":"C Nic Giolla Chomhaill","year":"2024","unstructured":"Nic Giolla Chomhaill C, Ward J, Dowling M. Fear of recurrence in women with ovarian cancer: a qualitative evidence synthesis. Eur J Oncol Nurs. 2024;68:102487. https:\/\/doi.org\/10.1016\/j.ejon.2023.102487.","journal-title":"Eur J Oncol Nurs"},{"key":"4467_CR52","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1097\/01.NCC.0000281729.10362.3a","volume":"30","author":"E Ekwall","year":"2007","unstructured":"Ekwall E, Ternestedt B-M, Sorbe B. Recurrence of ovarian cancer-living in limbo. Cancer Nurs. 2007;30:270. https:\/\/doi.org\/10.1097\/01.NCC.0000281729.10362.3a.","journal-title":"Cancer Nurs"},{"key":"4467_CR53","doi-asserted-by":"publisher","first-page":"14","DOI":"10.5737\/1181912x1011421","volume":"10","author":"CS Davis","year":"2000","unstructured":"Davis CS, Zinkland JE, Fitch MI. Cancer treatment-induced menopause: meaning for breast and gynecological cancer survivors. Can Oncol Nurs J Rev Can Soins Infirm En Oncol. 2000;10:14\u201321.","journal-title":"Can Oncol Nurs J Rev Can Soins Infirm En Oncol"},{"key":"4467_CR54","unstructured":"National cancer institute. Cancer stat facts: ovarian cancer. SEER. https:\/\/seer.cancer.gov\/statfacts\/html\/ovary.html. Accessed 2 Mar 2026."},{"key":"4467_CR55","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1016\/j.ygyno.2006.08.036","volume":"104","author":"K Hodgkinson","year":"2007","unstructured":"Hodgkinson K, Butow P, Fuchs A, Hunt GE, Stenlake A, Hobbs KM, et al. Long-term survival from gynecologic cancer: psychosocial outcomes, supportive care needs and positive outcomes. Gynecol Oncol. 2007;104:381\u20139. https:\/\/doi.org\/10.1016\/j.ygyno.2006.08.036.","journal-title":"Gynecol Oncol"},{"key":"4467_CR56","doi-asserted-by":"publisher","first-page":"450","DOI":"10.6004\/jnccn.2023.0026","volume":"21","author":"MB Riba","year":"2023","unstructured":"Riba MB, Donovan KA, Ahmed K, Andersen B, Braun I, Breitbart WS, et al. NCCN Guidelines\u00ae insights: distress management, version 2.2023: featured updates to the NCCN guidelines. J Natl Compr Canc Netw. 2023;21:450\u20137. https:\/\/doi.org\/10.6004\/jnccn.2023.0026.","journal-title":"J Natl Compr Canc Netw"},{"key":"4467_CR57","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1016\/j.ygyno.2022.06.016","volume":"166","author":"JA Wall","year":"2022","unstructured":"Wall JA, Lipking K, Smith HJ, Huh WK, Salter T, Liang MI. Moderate to severe distress in half of ovarian cancer patients undergoing treatment highlights a need for more proactive symptom and psychosocial management. Gynecol Oncol. 2022;166:503\u20137. https:\/\/doi.org\/10.1016\/j.ygyno.2022.06.016.","journal-title":"Gynecol Oncol"},{"key":"4467_CR58","doi-asserted-by":"publisher","first-page":"1294","DOI":"10.1002\/pon.1693","volume":"19","author":"A Bonacchi","year":"2010","unstructured":"Bonacchi A, Rossi A, Bellotti L, Franco S, Toccafondi A, Miccinesi G, et al. Assessment of psychological distress in cancer patients: a pivotal role for clinical interview. Psychooncol. 2010;19:1294\u2013302. https:\/\/doi.org\/10.1002\/pon.1693.","journal-title":"Psychooncol"},{"key":"4467_CR59","doi-asserted-by":"publisher","DOI":"10.1002\/pon.6255","volume":"33","author":"K Webb","year":"2024","unstructured":"Webb K, Sharpe L, Russell H, Shaw J. Fear of cancer recurrence in ovarian cancer caregivers: a qualitative study. Psychooncology. 2024;33:e6255. https:\/\/doi.org\/10.1002\/pon.6255.","journal-title":"Psychooncology"},{"key":"4467_CR60","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1017\/S1478951519000622","volume":"18","author":"CY Ochoa","year":"2020","unstructured":"Ochoa CY, Lunsford NB, Smith JL. Impact of informal cancer caregiving across the cancer experience: a systematic literature review of quality of life. Palliat Support Care. 2020;18:220\u201340. https:\/\/doi.org\/10.1017\/S1478951519000622.","journal-title":"Palliat Support Care"},{"key":"4467_CR61","doi-asserted-by":"publisher","first-page":"9461","DOI":"10.1007\/s00432-023-04753-8","volume":"149","author":"A Kiemen","year":"2023","unstructured":"Kiemen A, Czornik M, Weis J. How effective is peer-to-peer support in cancer patients and survivors? A systematic review. J Cancer Res Clin Oncol. 2023;149:9461\u201385. https:\/\/doi.org\/10.1007\/s00432-023-04753-8.","journal-title":"J Cancer Res Clin Oncol"},{"key":"4467_CR62","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1007\/s11764-023-01515-w","volume":"19","author":"Z Li","year":"2025","unstructured":"Li Z, Laginha K-J, Boyle F, Daly M, Dinner F, Hirsch P, et al. Professionally led support groups for people living with advanced or metastatic cancer: a systematic scoping review of effectiveness and factors critical to implementation success within real-world healthcare and community settings. J Cancer Surviv. 2025;19:957\u201377. https:\/\/doi.org\/10.1007\/s11764-023-01515-w.","journal-title":"J Cancer Surviv"},{"key":"4467_CR63","doi-asserted-by":"publisher","first-page":"2898","DOI":"10.1016\/j.clnu.2021.02.005","volume":"40","author":"M Muscaritoli","year":"2021","unstructured":"Muscaritoli M, Arends J, Bachmann P, Baracos V, Barthelemy N, Bertz H, et al. ESPEN practical guideline: clinical nutrition in cancer. Clin Nutr. 2021;40:2898\u2013913. https:\/\/doi.org\/10.1016\/j.clnu.2021.02.005.","journal-title":"Clin Nutr"},{"key":"4467_CR64","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejso.2023.107074","volume":"50","author":"J Arends","year":"2024","unstructured":"Arends J. Malnutrition in cancer patients: causes, consequences and treatment options. Eur J Surg Oncol. 2024;50:107074. https:\/\/doi.org\/10.1016\/j.ejso.2023.107074.","journal-title":"Eur J Surg Oncol"},{"key":"4467_CR65","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1080\/01635581.2016.1159702","volume":"68","author":"GW Yim","year":"2016","unstructured":"Yim GW, Eoh KJ, Kim SW, Nam EJ, Kim YT. Malnutrition identified by the nutritional risk index and poor prognosis in advanced epithelial ovarian carcinoma. Nutr Cancer. 2016;68:772\u20139. https:\/\/doi.org\/10.1080\/01635581.2016.1159702.","journal-title":"Nutr Cancer"},{"key":"4467_CR66","doi-asserted-by":"publisher","first-page":"e992","DOI":"10.1200\/OP.20.00704","volume":"17","author":"G Liposits","year":"2021","unstructured":"Liposits G, Orrevall Y, Kaasa S, \u00d6sterlund P, Cederholm T. Nutrition in cancer care: a brief, practical guide with a focus on clinical practice. JCO Oncol Pract. 2021;17:e992\u20138. https:\/\/doi.org\/10.1200\/OP.20.00704.","journal-title":"JCO Oncol Pract"},{"key":"4467_CR67","doi-asserted-by":"publisher","DOI":"10.1016\/j.maturitas.2024.107938","volume":"183","author":"S Benna-Doyle","year":"2024","unstructured":"Benna-Doyle S, Baguley BJ, Laing E, Kiss N. Nutritional interventions during treatment for ovarian cancer: a narrative review and recommendations for future research. Maturitas. 2024;183:107938. https:\/\/doi.org\/10.1016\/j.maturitas.2024.107938.","journal-title":"Maturitas"},{"key":"4467_CR68","doi-asserted-by":"publisher","first-page":"2003","DOI":"10.1016\/j.jand.2017.07.015","volume":"117","author":"WI Swan","year":"2017","unstructured":"Swan WI, Vivanti A, Hakel-Smith NA, Hotson B, Orrevall Y, Trostler N, et al. Nutrition care process and model update: toward realizing people-centered care and outcomes management. J Acad Nutr Diet. 2017;117:2003\u201314. https:\/\/doi.org\/10.1016\/j.jand.2017.07.015.","journal-title":"J Acad Nutr Diet"},{"key":"4467_CR69","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1097\/MCO.0000000000000389","volume":"20","author":"H Jager-Wittenaar","year":"2017","unstructured":"Jager-Wittenaar H, Ottery FD. Assessing nutritional status in cancer: role of the patient-generated subjective global assessment. Curr Opin Clin Nutr Metab Care. 2017;20:322\u20139. https:\/\/doi.org\/10.1097\/MCO.0000000000000389.","journal-title":"Curr Opin Clin Nutr Metab Care"},{"key":"4467_CR70","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.clnu.2018.08.002","volume":"38","author":"T Cederholm","year":"2019","unstructured":"Cederholm T, Jensen GL, Correia MITD, Gonzalez MC, Fukushima R, Higashiguchi T, et al. GLIM criteria for the diagnosis of malnutrition \u2013 a consensus report from the global clinical nutrition community. Clin Nutr. 2019;38:1\u20139. https:\/\/doi.org\/10.1016\/j.clnu.2018.08.002.","journal-title":"Clin Nutr"},{"key":"4467_CR71","unstructured":"C\u00e1ceres Lavernia H, Neninger Vinageras E, Men\u00e9ndez Alfonso Y, Barreto Peni\u00e9 J. Intervenci\u00f3n nutricional en el paciente con c\u00e1ncer. Rev Cuba Med 2016; 55:0"},{"key":"4467_CR72","doi-asserted-by":"publisher","DOI":"10.3390\/nu15245068","volume":"15","author":"M Garutti","year":"2023","unstructured":"Garutti M, Noto C, Past\u00f2 B, Cucciniello L, Alajmo M, Casirati A, et al. Nutritional management of oncological symptoms: a comprehensive review. Nutrients. 2023;15:5068. https:\/\/doi.org\/10.3390\/nu15245068.","journal-title":"Nutrients"},{"key":"4467_CR73","unstructured":"International agency for research on cancer. European code against cancer, 5th edition: 14 ways you can help prevent cancer. https:\/\/cancer-code-europe.iarc.who.int\/. Accessed 2 Mar 2026."},{"key":"4467_CR74","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1016\/j.ygyno.2020.06.485","volume":"158","author":"TL Jones","year":"2020","unstructured":"Jones TL, Sandler CX, Spence RR, Hayes SC. Physical activity and exercise in women with ovarian cancer: a systematic review. Gynecol Oncol. 2020;158:803\u201311. https:\/\/doi.org\/10.1016\/j.ygyno.2020.06.485.","journal-title":"Gynecol Oncol"},{"key":"4467_CR75","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1136\/ijgc-2020-002107","volume":"31","author":"T Jones","year":"2021","unstructured":"Jones T, Sandler C, Vagenas D, Janda M, Obermair A, Hayes S. Physical activity levels among ovarian cancer survivors: a prospective longitudinal cohort study. Int J Gynecol Cancer. 2021;31:553\u201361. https:\/\/doi.org\/10.1136\/ijgc-2020-002107.","journal-title":"Int J Gynecol Cancer"},{"key":"4467_CR76","doi-asserted-by":"publisher","first-page":"2375","DOI":"10.1249\/MSS.0000000000002116","volume":"51","author":"KL Campbell","year":"2019","unstructured":"Campbell KL, Winters-Stone KM, Wiskemann J, May AM, Schwartz AL, Courneya KS, et al. Exercise guidelines for cancer survivors: consensus statement from international multidisciplinary roundtable. Med Sci Sports Exerc. 2019;51:2375. https:\/\/doi.org\/10.1249\/MSS.0000000000002116.","journal-title":"Med Sci Sports Exerc"},{"key":"4467_CR77","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1111\/IGC.0b013e31819902ec","volume":"19","author":"C Stevinson","year":"2009","unstructured":"Stevinson C, Steed H, Faught W, Tonkin K, Vallance JK, Ladha AB, et al. Physical activity in ovarian cancer survivors. Int J Gynecol Cancer. 2009;19:73\u20138. https:\/\/doi.org\/10.1111\/IGC.0b013e31819902ec.","journal-title":"Int J Gynecol Cancer"},{"key":"4467_CR78","doi-asserted-by":"publisher","first-page":"e2326463","DOI":"10.1001\/jamanetworkopen.2023.26463","volume":"6","author":"A Cao","year":"2023","unstructured":"Cao A, Cartmel B, Li F-Y, Gottlieb LT, Harrigan M, Ligibel JA, et al. Effect of exercise on chemotherapy-induced peripheral neuropathy among patients treated for ovarian cancer: a secondary analysis of a randomized clinical trial. JAMA Netw Open. 2023;6:e2326463. https:\/\/doi.org\/10.1001\/jamanetworkopen.2023.26463.","journal-title":"JAMA Netw Open"},{"key":"4467_CR79","doi-asserted-by":"publisher","DOI":"10.1136\/ijgc-2024-005686","author":"R Sebio-Garcia","year":"2025","unstructured":"Sebio-Garcia R, Celada-Castro C, Arguis MJ, Sis\u00f3 M, Torn\u00e9 A, Tena B, et al. Multimodal prehabilitation improves functional capacity in patients with advanced ovarian cancer undergoing cytoreductive surgery. Int J Gynecol Cancer. 2025. https:\/\/doi.org\/10.1136\/ijgc-2024-005686.","journal-title":"Int J Gynecol Cancer"},{"key":"4467_CR80","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14071635","volume":"14","author":"B Diaz-Feijoo","year":"2022","unstructured":"Diaz-Feijoo B, Agusti-Garcia N, Sebio R, L\u00f3pez-Hern\u00e1ndez A, Sis\u00f3 M, Glickman A, et al. Feasibility of a multimodal prehabilitation programme in patients undergoing cytoreductive surgery for advanced ovarian cancer: a pilot study. Cancers. 2022;14:1635. https:\/\/doi.org\/10.3390\/cancers14071635.","journal-title":"Cancers"},{"key":"4467_CR81","doi-asserted-by":"publisher","first-page":"1169","DOI":"10.1007\/s10151-023-02844-9","volume":"27","author":"M Paul","year":"2023","unstructured":"Paul M, Smart TF, Doleman B, Toft S, Williams JP, Lund JN, et al. A systematic review of the impact of postoperative aerobic exercise training in patients undergoing surgery for intra-abdominal cancers. Tech Coloproctol. 2023;27:1169\u201381. https:\/\/doi.org\/10.1007\/s10151-023-02844-9.","journal-title":"Tech Coloproctol"},{"key":"4467_CR82","first-page":"24","volume":"41","author":"S Casla-Barrio","year":"2018","unstructured":"Casla-Barrio S, Alfaro-Gamero J. Exercise oncology. From theory to the practice. Eur J Hum Mov. 2018;41:24\u201348.","journal-title":"Eur J Hum Mov"},{"key":"4467_CR83","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-023-07754-y","volume":"31","author":"C Schofield","year":"2023","unstructured":"Schofield C, Newton RU, Taaffe DR, Galv\u00e3o DA, Cohen PA, Meniawy TM, et al. Supervised resistance exercise for women with ovarian cancer who have completed first-line treatment: a pragmatic study. Support Care Cancer. 2023;31:304. https:\/\/doi.org\/10.1007\/s00520-023-07754-y.","journal-title":"Support Care Cancer"},{"key":"4467_CR84","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1007\/s00192-012-2026-2","volume":"24","author":"IE Nygaard","year":"2013","unstructured":"Nygaard IE, Hamad NM, Shaw JM. Activity restrictions after gynecologic surgery: is there evidence? Int Urogynecol J. 2013;24:719\u201324. https:\/\/doi.org\/10.1007\/s00192-012-2026-2.","journal-title":"Int Urogynecol J"},{"key":"4467_CR85","doi-asserted-by":"publisher","DOI":"10.1016\/j.jogoh.2023.102688","volume":"53","author":"S Tim","year":"2024","unstructured":"Tim S, Mazur-Bialy AI. Physiotherapy interventions in the treatment of pelvic floor dysfunctions after gynaecological oncology procedures: a systematic review. J Gynecol Obstet Hum Reprod. 2024;53:102688. https:\/\/doi.org\/10.1016\/j.jogoh.2023.102688.","journal-title":"J Gynecol Obstet Hum Reprod"},{"key":"4467_CR86","doi-asserted-by":"publisher","first-page":"1252","DOI":"10.1007\/s11764-023-01366-5","volume":"18","author":"K Toohey","year":"2024","unstructured":"Toohey K, Paterson C, Coltman CE. Barriers and enablers to participation in physical activity among women diagnosed with ovarian cancer. J Cancer Surviv. 2024;18:1252\u201363. https:\/\/doi.org\/10.1007\/s11764-023-01366-5.","journal-title":"J Cancer Surviv"},{"key":"4467_CR87","doi-asserted-by":"publisher","first-page":"1290747","DOI":"10.3389\/fonc.2023.1290747","volume":"13","author":"S Zhang","year":"2023","unstructured":"Zhang S, Zhang F, Yang F, Yang J, Zhang L, Xie J. Analysis of the status and factors influencing physical activity in patients undergoing ovarian cancer chemotherapy. Front Oncol. 2023;13:1290747. https:\/\/doi.org\/10.3389\/fonc.2023.1290747.","journal-title":"Front Oncol"},{"key":"4467_CR88","volume-title":"Motivational interviewing: preparing people for change","author":"WR Miller","year":"2002","unstructured":"Miller WR, Rollnick S. Motivational interviewing: preparing people for change. 2nd ed. New York, US: The Guilford Press; 2002.","edition":"2"},{"key":"4467_CR89","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1016\/j.ajog.2017.04.012","volume":"217","author":"M Whicker","year":"2017","unstructured":"Whicker M, Black J, Altwerger G, Menderes G, Feinberg J, Ratner E. Management of sexuality, intimacy, and menopause symptoms in patients with ovarian cancer. Am J Obstet Gynecol. 2017;217:395\u2013403. https:\/\/doi.org\/10.1016\/j.ajog.2017.04.012.","journal-title":"Am J Obstet Gynecol"},{"key":"4467_CR90","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1007\/s11930-022-00343-w","volume":"14","author":"C Benedict","year":"2022","unstructured":"Benedict C, Shaffer KM, Wirtz MR, Ford JS, Reese JB. Current considerations in interventions to address sexual function and improve care for women with cancer. Curr Sex Health Rep. 2022;14:222\u201330. https:\/\/doi.org\/10.1007\/s11930-022-00343-w.","journal-title":"Curr Sex Health Rep"},{"key":"4467_CR91","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1016\/j.ygyno.2023.11.001","volume":"179","author":"K Cotangco","year":"2023","unstructured":"Cotangco K, Pineda E, Hingarh V, Nyakudarika NC, Cohen JG, Holschneider CH. Integrating social care into gynecologic oncology: identifying and addressing patient\u2019s social needs. Gynecol Oncol. 2023;179:138\u201344. https:\/\/doi.org\/10.1016\/j.ygyno.2023.11.001.","journal-title":"Gynecol Oncol"},{"key":"4467_CR92","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1200\/JCO.2015.63.0830","volume":"34","author":"E Basch","year":"2016","unstructured":"Basch E, Deal AM, Kris MG, Scher HI, Hudis CA, Sabbatini P, et al. Symptom monitoring with patient-reported outcomes during routine cancer treatment: a randomized controlled trial. J Clin Oncol. 2016;34:557\u201365. https:\/\/doi.org\/10.1200\/JCO.2015.63.0830.","journal-title":"J Clin Oncol"},{"key":"4467_CR93","doi-asserted-by":"publisher","first-page":"111","DOI":"10.2147\/PROM.S297301","volume":"14","author":"R Campbell","year":"2023","unstructured":"Campbell R, King MT, Stockler MR, Lee YC, Roncolato FT, Friedlander ML. Patient-reported outcomes in ovarian cancer: facilitating and enhancing the reporting of symptoms, adverse events, and subjective benefit of treatment in clinical trials and clinical practice. Patient Relat Outcome Meas. 2023;14:111\u201326. https:\/\/doi.org\/10.2147\/PROM.S297301.","journal-title":"Patient Relat Outcome Meas"},{"key":"4467_CR94","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1093\/jnci\/85.5.365","volume":"85","author":"NK Aaronson","year":"1993","unstructured":"Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, et al. The European organization for research and treatment of cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst. 1993;85:365\u201376. https:\/\/doi.org\/10.1093\/jnci\/85.5.365.","journal-title":"J Natl Cancer Inst"},{"key":"4467_CR95","doi-asserted-by":"publisher","first-page":"1402","DOI":"10.1016\/S0959-8049(03)00307-1","volume":"39","author":"E Greimel","year":"2003","unstructured":"Greimel E, Bottomley A, Cull A, Waldenstrom A-C, Arraras J, Chauvenet L, et al. An international field study of the reliability and validity of a disease-specific questionnaire module (the QLQ-OV28) in assessing the quality of life of patients with ovarian cancer. Eur J Cancer. 2003;39:1402\u20138. https:\/\/doi.org\/10.1016\/S0959-8049(03)00307-1.","journal-title":"Eur J Cancer"},{"key":"4467_CR96","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1200\/JCO.1993.11.3.570","volume":"11","author":"DF Cella","year":"1993","unstructured":"Cella DF, Tulsky DS, Gray G, Sarafian B, Linn E, Bonomi A, et al. The functional assessment of cancer therapy scale: development and validation of the general measure. J Clin Oncol. 1993;11:570\u20139. https:\/\/doi.org\/10.1200\/JCO.1993.11.3.570.","journal-title":"J Clin Oncol"},{"key":"4467_CR97","doi-asserted-by":"publisher","first-page":"1809","DOI":"10.1200\/JCO.2001.19.6.1809","volume":"19","author":"K Basen-Engquist","year":"2001","unstructured":"Basen-Engquist K, Bodurka-Bevers D, Fitzgerald MA, Webster K, Cella D, Hu S, et al. Reliability and validity of the functional assessment of cancer therapy\u2013ovarian. J Clin Oncol. 2001;19:1809\u201317. https:\/\/doi.org\/10.1200\/JCO.2001.19.6.1809.","journal-title":"J Clin Oncol"},{"key":"4467_CR98","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1016\/j.ygyno.2021.08.022","volume":"163","author":"R Campbell","year":"2021","unstructured":"Campbell R, King MT, Ross TL, Cohen PA, Friedlander ML, Webb PM. Development and validation of the measure of ovarian symptoms and treatment concerns for surveillance (MOST-S26): an instrument to complement the clinical follow-up of women with ovarian cancer after completion of first-line treatment. Gynecol Oncol. 2021;163:398\u2013407. https:\/\/doi.org\/10.1016\/j.ygyno.2021.08.022.","journal-title":"Gynecol Oncol"},{"key":"4467_CR99","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.885910","volume":"12","author":"V Escudero-Vilaplana","year":"2022","unstructured":"Escudero-Vilaplana V, Bernal E, Casado G, Collado-Borrell R, Diez-Fern\u00e1ndez R, Fern\u00e1ndez Rom\u00e1n AB, et al. Defining a standard set of patient-reported outcomes for patients with advanced ovarian cancer. Front Oncol. 2022;12:885910. https:\/\/doi.org\/10.3389\/fonc.2022.885910.","journal-title":"Front Oncol"},{"key":"4467_CR100","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1016\/j.ygyno.2022.08.006","volume":"167","author":"A Madariaga","year":"2022","unstructured":"Madariaga A, Mitchell SA, Pittman T, Wang L, Bowering V, Kavak N, et al. Patient self-reporting of tolerability using PRO-CTCAE in a randomized double-blind, placebo-controlled phase II trial comparing gemcitabine in combination with adavosertib or placebo in patients with platinum resistant or refractory epithelial ovarian carcinoma. Gynecol Oncol. 2022;167:226\u201333. https:\/\/doi.org\/10.1016\/j.ygyno.2022.08.006.","journal-title":"Gynecol Oncol"}],"container-title":["Clinical and Translational Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-026-04467-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12094-026-04467-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-026-04467-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T17:19:55Z","timestamp":1783358395000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12094-026-04467-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,6]]},"references-count":100,"alternative-id":["4467"],"URL":"https:\/\/doi.org\/10.1007\/s12094-026-04467-6","relation":{},"ISSN":["1699-3055"],"issn-type":[{"value":"1699-3055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,6]]},"assertion":[{"value":"22 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"MPBG: Holds a consultancy or advisory role with AbbVie, AstraZeneca, Genmab, Eisai, GSK, MSD, PharmaMar, Pharma&, and Regeneron; is a speaker for AbbVie, AstraZeneca, Eisai, GSK, MSD, Pharma&, and Regeneron; and has received travel grants and accommodation from AstraZeneca, GSK, and MSD. She is the vice president of GEICO (Spanish Gynaecological Cancer Research Group [non-financial]). AG: Has received honoraria or consultation fees from GSK, MSD, AstraZeneca, Clovis, AbbVie, Eisai, and Pharma&; participated in a company-sponsored speaker\u2019s bureau for Roche, AstraZeneca, MSD, Clovis, and GSK; and received support for travel\/accommodation\/expenses from Roche, MSD, GSK, AstraZeneca, and PharmaMar. AM: Has received honoraria from AstraZeneca, AbbVie, GSK, Daiichi Sankyo, Eisai, Genmab, MSD, PharmaMar, and Pharma&. EGA: Has received advisory or consultancy honoraria from AstraZeneca, MSD, Clovis Oncology, GSK, PharmaMar, Roche, Pharma&, and AbbVie; honoraria for speaker\u2019s bureau\/expert testimony from AstraZeneca, MSD, PharmaMar, Pharma&, Roche, GSK, Clovis, Eisai, and AbbVie; and support for travel\/accommodation\/expenses from Roche, GSK and Astra Zeneca. LGG: Has received consulting fees from Daiichi Sankyo, AbbVie, GSK, AstraZeneca, MSD, and Clovis Oncology; payment or honoraria for lectures, presentations, speaker\u2019s bureaus, manuscript writing, or educational events from GSK, AstraZeneca, MSD, and Eisai; support for attending meetings and\/or travel from GSK, AstraZeneca, and MSD; and has participated in a data safety monitoring board or advisory board for Daiichi Sanyo. MBO: Has participated in speaking and teaching activities for GSK, MSD-AstraZeneca, Sysmex, Johnson & Johnson, Sanofi, Corza Medical, and Procare Health; advisory boards for MSD-AstraZeneca, GSK, and Johnson & Johnson; and has received support for travel and accommodation from GSK, MSD-AstraZeneca, and Procare Health. ABSH: Has received honoraria or consultation fees from AstraZeneca, MSD, and GSK; participated in a company-sponsored speaker\u2019s bureau for AstraZeneca, MSD, GSK, and Pharma&; and received support for travel\/accommodation\/expenses from GSK, MSD, Roche, Pharma&, and AstraZeneca. XMG: Has participated in advisory boards for AstraZeneca, Lilly, Amgen, GSK, Janssen, Illumina, MiMark Diagnostics, MSD, Daiichi Sankyo, and AbbVie. SCB: Has participated in speaking and teaching activities for MSD-AstraZeneca, Astellas, Johnson & Johnson, Novartis, Ipsen, Eisai, and Servier; and received research funds from AstraZeneca. FC: Has participated in speaking and teaching activities for GSK, MSD, AstraZeneca, Daiichi Sankyo, Johnson & Johnson, Novartis, Jazz Pharmaceuticals, Merck, Ipsen, Jansen, Almirall, Fundaci\u00f3n de Estudios Mastol\u00f3gicos, Viatris, Pfizer, Sandoz, Bayer, Incyte Biosciences Iberia, Lilly, Takeda, and Roche; in advisory boards for Merck and AstraZeneca; and has received professional or consulting fees from ASACO (Asociaci\u00f3n de Afectadas por C\u00e1ncer de Ovario y Ginecol\u00f3gico). MGC, MNL, MRT, and CHR declare that they have no conflicts of interest related to the present work.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This review article is based on published evidence and expert opinion of the authors. No new studies with human participants or animals were performed for this review.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval and consent to participate"}}]}}